1. Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer 
Ana Belén Custodio, MD, José Luis González-Larriba, MD, PhD, Jana Bobokova, MD, Antonio Calles, MD, Rafael Álvarez, MD, Eugenio Cuadrado, MD, Aranzazu Manzano, MD, Eduardo Díaz-Rubio, MD, PhD 
Journal of Thoracic Oncology 
Volume 4, Issue 7, Pages (July 2009)
DOI: /JTO.0b013e3181a4b8fb
Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Kaplan-Meier survival estimates for a group of patients with stage IA disease from the Duke, ACOSOG, and CALGB cohorts and the subgroups predicted to have either a high probability (>0.5) or a low probability (≤0.5) of recurrence by the application of the Lung Metagene Model.
Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb)
Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Kaplan-Meier estimates of overall survival and relapse-free survival for the 101 patients with NSCLC (Panel A and Panel B, respectively) and for the 59 patients with stage I or stage II disease (Panel C and Panel D, respectively), according to the Five-Gene Signature.
Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb)
Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

4. FIGURE 3
Kaplan-Meier estimates of disease-free survival (A) and overall survival (B) among patients with stage I NSCLC according to ERCC1 and RRM1 expression levels.
Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb)
Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

5. FIGURE 4
Event-free and median survival according to expression of TRX (A and C) and BRCA1 (B and D).
Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb)
Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

6. FIGURE 5
A, Relapse-free survival and overall survival curves for low-tubulin expressors according to treatment assignment; B, Relapse-free survival and overall survival curves for high-tubulin expressors according to treatment assignment. vin/cisp, vinorelbine/cisplatin.
Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb)
Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

7. FIGURE 6
Overall survival curves of patients with p53 protein expression (immunohistochemistry) results. (A) p53 IHC results known; (B) p53 IHC results, observation; (C) p53 IHC positive; and (D) p53 IHC negative.
Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb)
Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

8. FIGURE 7
Odds ratios for recurrence among case patients when compared with controls, according to methylated gene and site.
Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181a4b8fb)
Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions